Memphasys Limited (FRA:IG7)
Germany flag Germany · Delayed Price · Currency is EUR
0.0015
+0.0005 (50.00%)
At close: Mar 27, 2026
Market Cap8.51M +33.6%
Revenue (ttm)121.56K +52.1%
Net Income-2.51M
EPS-0.00
Shares Outn/a
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volume1,589
Open0.0015
Previous Close0.0010
Day's Range0.0015 - 0.0015
52-Week Range0.0010 - 0.0055
Betan/a
RSI45.79
Earnings DateMar 3, 2026

About Memphasys

Memphasys Limited develops, manufactures, and sells cell and protein separation devices, and related consumables for the healthcare, veterinary, and biotechnology market sectors in Australia. The company offers Felix system, a device separates sperm from raw semen by electrophoresis process and size exclusion membranes. It also provides RoXsta, a rapid in vitro antioxidant assessment; and AI-Port, an ambient temperature semen transport device for artificial insemination in animals. In addition, the company develops ambient temperature storage p... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2006
Employees 24
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol IG7

Financial Performance

In fiscal year 2025, Memphasys's revenue was 526,921, an increase of 237.77% compared to the previous year's 156,000. Losses were -5.04 million, -6.19% less than in 2024.

Financial numbers in AUD Financial Statements